Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Gains from Investment Securities (2016 - 2025)

Integra Lifesciences Holdings' Gains from Investment Securities history spans 15 years, with the latest figure at $17.3 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 12650.74% year-over-year to $17.3 million; the TTM value through Dec 2025 reached $2.7 million, down 23.16%, while the annual FY2025 figure was $2.7 million, 23.16% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $17.3 million at Integra Lifesciences Holdings, up from -$14.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $17.3 million in Q4 2025 and bottomed at -$42.7 million in Q3 2022.
  • The 5-year median for Gains from Investment Securities is $1.5 million (2023), against an average of $146388.9.
  • The largest YoY upside for Gains from Investment Securities was 12650.74% in 2025 against a maximum downside of 1019.81% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $3.6 million in 2021, then plummeted by 123.1% to -$823000.0 in 2022, then skyrocketed by 660.15% to $4.6 million in 2023, then plummeted by 97.05% to $136000.0 in 2024, then surged by 12650.74% to $17.3 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Gains from Investment Securities are $17.3 million (Q4 2025), -$14.4 million (Q3 2025), and -$2.3 million (Q2 2025).